SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
ID: 349231Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349231

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-219.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, aimed at providing technical assistance and late-stage development support for small business concerns (SBCs) transitioning previously funded SBIR and STTR projects to commercialization. This funding opportunity focuses on addressing the funding gap in the commercialization process by supporting activities such as IND-enabling studies, manufacturing costs, and regulatory assistance, which are not typically covered by Phase II or IIB grants. Eligible applicants include SBCs with active Phase II or IIB awards within the past 36 months, with budgets reaching up to $4,091,634, while clinical trials are explicitly excluded. Interested parties should note that the application deadline is April 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-219.html
    The Notice of Funding Opportunity (NOFO) from the Department of Health and Human Services outlines the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, encouraging small business concerns (SBCs) to transition previously funded SBIR and STTR projects towards commercialization. The program focuses on providing technical assistance and late-stage research and development not covered by typical Phase II or IIB grants, such as IND-enabling studies and manufacturing costs. Eligibility is restricted to SBCs with active Phase II or IIB awards within the past 36 months. Budgets can reach up to $4,091,634, with specific limitations for participating organizations, including caps ranging from $250,000 to $2,000,000 based on the institute. The application deadlines span from September 2023 to April 2025, and clinical trials are not permitted under this funding opportunity. Overall, the intent of this NOFO is to address the funding gap encountered in the commercialization process for biotechnology products, facilitating advancements that may attract further investments and partnerships.
    Similar Opportunities
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to announce the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, aimed at supporting small business concerns (SBCs) in transitioning their previously funded SBIR and STTR Phase II and Phase IIB projects to commercialization. This program will provide additional support for technical assistance and later-stage research and development (R&D), which may include critical studies, IND-enabling studies, clinical trials, and regulatory assistance, thereby enhancing the potential for successful market entry of innovative health solutions. The solicitation for applications is expected to be published on October 1, 2025, with a closing date of January 5, 2026, and an estimated award date of June 1, 2026. Interested applicants can reach out to the NIH SEED Office at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) to support early-career scientists transitioning into entrepreneurial roles within small businesses. This funding opportunity aims to facilitate the career development of investigators by providing entrepreneurial training, mentorship, and support for research and development projects that align with NIH's mission to improve health. Eligible small business concerns (SBCs) can apply for Phase I and Fast-Track grants, with funding amounts typically reaching $306,872 for Phase I and $2,045,816 for Phase II awards. Applications will be accepted starting August 5, 2024, with a closing date of April 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-134.html.
    NIH and CDC Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC), is offering a Small Business Innovation Research (SBIR) Grant opportunity for United States small business concerns (SBCs) to submit applications for various phases of research and development, including Phase I, Phase II, Direct to Phase II, Fast-Track, and Phase IIB grants. Eligible applicants must possess the necessary research capabilities and technological expertise to support the R&D missions of the NIH and CDC, with a focus on health-related innovations. This funding opportunity is significant as it encourages collaboration among small businesses to advance health research, with applications expected to be solicited following the reauthorization of the SBIR program. Interested parties can reach out to the NIH SEED Office at SEEDinfo@nih.gov or call 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a closing date for applications anticipated on January 5, 2026.
    NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed) aimed at encouraging United States small business concerns (SBCs) to engage in research and development projects aligned with NIH's mission. Eligible applicants, defined as SBCs by the Small Business Administration, are invited to prepare for future submissions of Phase I, Phase II, Fast-Track, and Phase IIB grant applications, although applications are not currently being solicited. This funding opportunity is significant for fostering innovative health-related research and collaboration among small businesses and NIH institutes. Interested parties can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a projected award date of June 1, 2026.
    NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) to support pre-clinical research aimed at bridging funding gaps that impede the commercialization of medical biotechnology products. This funding opportunity specifically targets previously funded SBIR or STTR Phase II projects, with the objective of advancing products or technologies that require federal regulatory approval, while fostering partnerships between small businesses and external investors to enhance commercialization prospects. Applicants are encouraged to secure independent third-party funding that equals or exceeds one-third of the requested NINDS funds, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in the research environment. The application deadline is April 5, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-222.html.
    PHS 2025-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting eligible United States small business concerns (SBCs) to prepare applications for the PHS 2025-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, which includes Phase I, Phase II, Fast-Track, and Phase IIB grants. This opportunity aims to support innovative research and development projects that align with the NIH's mission, encouraging collaborations that leverage the technological expertise of small businesses in the health sector. The solicitation is contingent upon the reauthorization of the STTR program, with an estimated synopsis posting date of October 1, 2025, and a closing date of January 5, 2026. Interested applicants can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or call 301-827-8595 for further information.
    Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for Small Business Innovation Research (SBIR) Phase IIB Bridge Awards aimed at accelerating the development of cancer-relevant technologies toward commercialization. This funding opportunity is designed for small business concerns (SBCs) that have previously received SBIR or STTR Phase II awards from any Federal agency and are seeking additional funding to transition their projects to the commercialization stage. The initiative emphasizes the importance of fostering partnerships between awardees and third-party investors to support the capital-intensive steps necessary for bringing new products and services to market. While applications are not currently being solicited, the NOFO is expected to be published in Summer 2025, with an anticipated application due date in Fall 2025. For further inquiries, interested parties can contact Jonathan Franca-Koh, Ph.D., M.B.A. at 240-618-0984 or via email at francakohjc@mail.nih.gov.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering NINDS Renewal Awards of Small Business Innovation Research (SBIR) Phase II Grants (Phase IIB) to support clinical trials and clinical research projects focused on neurological disorders. This funding opportunity encourages small business concerns (SBCs) to seek additional funding for projects previously funded by NIH SBIR and STTR Phase II awards, with an emphasis on facilitating the transition of these projects to commercialization through partnerships with third-party investors. The initiative aims to address the "Valley of Death" funding gap in medical biotechnology, particularly for products related to the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Interested applicants must submit a Commercialization Plan and a Plan for Enhancing Diverse Perspectives (PEDP), with the application opening on August 5, 2024, and a closing date of April 5, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)" to support early-career scientists in their transition to entrepreneurship. This grant aims to facilitate the development of small business concerns (SBCs) by employing researchers as Program Directors/Principal Investigators (PDs/PIs), providing them with essential entrepreneurial training, mentorship, and a structured framework for developing commercially viable biomedical technologies. The program is particularly focused on enhancing the entrepreneurial skills of scientists with strong technical expertise but limited experience in entrepreneurship, thereby aligning with NIH's mission to improve health. Interested applicants must be U.S.-based small businesses, and the application process will commence in September 2024, with a closing date of April 5, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-133.html.